Novel Approach to Cancer Immunotherapy Shows Promise

Scientists from Johns Hopkins, using software from Insilico Medicine, say they have invented a new class of immunotherapeutics to fight cancer. The team published its study (“ Bifunctional Immune Checkpoint-Targeted Antibody-Ligand Traps That Simultaneously Disable TGFβ Enhance the Efficacy of Cancer Immunotherapy ”) in  Nature Communications .“A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T